Clinical Trial in Chinese Healthy Volunteers of GB222

Summary

The primary objective of this study is to evaluate the similarity of the primary pharmacokinetic (PK) parameter AUC0-t of GB222 and bevacizumab after single administration; the secondary objective is to observe the safety and similarities and safety of other pharmacokinetic (PK) parameters (Cmax, AUC0-∞ etc.) and immunogenicity of GB222 and bevacizumab after single administration.

Timeline

Start

2017-04-24

Primary completion

2020-08

Completion

2020-11

Drugs

Indications